Noopept vs Semax
A neutral, side-by-side comparison of two nootropic & cognitive peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Noopept
Dipeptide-derived nootropic developed in Russia and used across Eastern Europe as a cognitive enhancer and neuroprotective agent. Structurally related to piracetam but estimated to be approximately 1000× more potent by weight. Rapidly crosses the blood-brain barrier and is hydrolyzed to the endogenous neuropeptide cycloprolylglycine, which is proposed as its primary active metabolite.
Full profileSemax
Semax is a synthetic heptapeptide derived from adrenocorticotropic hormone (ACTH) — specifically the 4–7 fragment modified with a C-terminal Pro-Gly-Pro extension for stability. Developed in Russia in the 1980s and used clinically there for stroke recovery, cognitive enhancement, and neuroprotection, it is one of the most researched nootropic peptides with a decades-long safety record in Eastern European clinical practice. Its primary mechanism involves potent upregulation of BDNF (Brain-Derived Neurotrophic Factor).
Full profile| Noopept | Semax | |
|---|---|---|
| Category | Nootropic & Cognitive | Nootropic & Cognitive |
| Also known as | GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, N-Phenylacetyl-L-Prolylglycine Ethyl Ester | ACTH(4-7)PGP, Met-Glu-His-Phe-Pro-Gly-Pro |
| Evidence | Research-stage | Investigational (in trials) |
| Dosing range | 5mg–20mg mg, 1–3x daily oral or sublingual (8–12 week cycles) | 200mcg–900mcg mcg, Once or twice daily (intranasal most common) |
| Administration | Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal | Intranasal (preferred — high CNS bioavailability), Subcutaneous injection |
| Key side effects | Headache (especially without choline supplementation), Irritability, Brain fog at high doses, Insomnia (if taken too late in day) | Mild anxiety or restlessness at high doses, Nasal irritation (intranasal route), Increased energy / difficulty sleeping if dosed too late in the day, Mild appetite suppression |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: Noopept is research-stage, while Semax is investigational (in trials).
- Administration: Noopept — Oral (capsule/powder), Sublingual (dissolved under tongue), Intranasal; Semax — Intranasal (preferred — high CNS bioavailability), Subcutaneous injection.
- Dosing units differ: Noopept is dosed in mg, Semax in mcg — they operate at different scales.
- Frequency: Noopept is typically 1–3x daily oral or sublingual (8–12 week cycles); Semax is Once or twice daily (intranasal most common).
- Research depth: this profile cites 2 sources for Noopept vs 3 for Semax.
How each works
Noopept
Noopept (GVS-111) enhances AMPA-receptor function and increases expression of BDNF and NGF in the hippocampus and basal forebrain. Its active metabolite cycloprolylglycine acts as an endogenous neuropeptide with anxiolytic and cognition-enhancing properties. Russian clinical trials demonstrate cognitive improvement in subjects with cognitive impairment, with a better tolerability profile than piracetam at equipotent doses.
Semax
Semax increases BDNF expression in the hippocampus and frontal cortex by 1.3–1.6x at research doses in rodent models. It also upregulates NGF (nerve growth factor) and modulates serotonin, dopamine, and NMDA receptor systems. Russian clinical data (not yet replicated in Western trials) suggests efficacy in ischemic stroke recovery, ADHD, glaucoma, and cognitive decline. The Pro-Gly-Pro C-terminal extension dramatically improves resistance to enzymatic degradation compared to native ACTH(4-7).
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.